{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:27:42Z","timestamp":1761989262179,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12020-018-1808-9","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T10:43:07Z","timestamp":1541673787000},"page":"43-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance"],"prefix":"10.1007","volume":"64","author":[{"given":"Yushi","family":"Hirota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Takabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3035-4155","authenticated-orcid":false,"given":"Yuko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"1808_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"J.J. Meier, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728\u2013742 (2012)","journal-title":"Nat. Rev. Endocrinol."},{"key":"1808_CR2","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"T. Vilsb\u00f8ll, M. Christensen, A.E. Junker, F.K. Knop, L.L. Gluud, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012)","journal-title":"BMJ"},{"key":"1808_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Z.Z. Htike, F. Zaccardi, D. Papamargaritis, D.R. Webb, K. Khunti, M.J. Davies, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 19, 524\u2013536 (2017)","journal-title":"Diabetes Obes. Metab."},{"key":"1808_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154206","volume":"11","author":"Z Li","year":"2016","unstructured":"Z. Li, Y. Zhang, X. Quan, Z. Yang, X. Zeng, L. Ji, F. Sun, S. Zhan, Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS ONE 11, e0154206 (2016)","journal-title":"PLoS ONE"},{"key":"1808_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; LEADER Steering Committee; LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016)","journal-title":"N. Engl. J. Med."},{"key":"1808_CR6","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. J\u00f3dar, L.A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M.L. Warren, V. Woo, O. Hansen, A.G. Holst, J. Pettersson, T. Vilsb\u00f8ll; SUSTAIN-6 Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016)","journal-title":"N. Engl. J. Med."},{"key":"1808_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","volume":"326","author":"M Gutniak","year":"1992","unstructured":"M. Gutniak, C. Orskov, J.J. Holst, B. Ahr\u00e9n, S. Efendic, Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326, 1316\u20131322 (1992)","journal-title":"N. Engl. J. Med."},{"key":"1808_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, W. Creutzfeldt, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741\u2013744 (1993)","journal-title":"Diabetologia"},{"key":"1808_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.2337\/diabetes.54.7.2212","volume":"54","author":"JJ Meier","year":"2005","unstructured":"J.J. Meier, G. Kemmeries, J.J. Holst, M.A. Nauck, Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54, 2212\u20132218 (2005)","journal-title":"Diabetes"},{"key":"1808_CR10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1210\/jc.2003-030049","volume":"88","author":"JJ Meier","year":"2003","unstructured":"J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, W.E. Schmidt, M.A. Nauck, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 2719\u20132725 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1808_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"M. Zander, S. Madsbad, J.L. Madsen, J.J. Holst, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824\u2013830 (2002)","journal-title":"Lancet"},{"key":"1808_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"A. Flint, A. Raben, A. Astrup, J.J. Holst, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515\u2013520 (1998)","journal-title":"J. Clin. Invest."},{"key":"1808_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"M.D. Turton, D. O\u2019Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, S.R. Bloom, A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69\u201372 (1996)","journal-title":"Nature"},{"key":"1808_CR14","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"A. Astrup, S. R\u00f6ssner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M.F. Rasmussen, M.E. Lean; NN8022-1807 Study Group, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606\u20131616 (2009)","journal-title":"Lancet"},{"key":"1808_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Roux le","year":"2017","unstructured":"C.W. le Roux, A. Astrup, K. Fujioka, F. Greenway, D.C.W. Lau, L. Van Gaal, R.V. Ortiz, J.P.H. Wilding, T.V. Skj\u00f8th, L.S. Manning, X. Pi-Sunyer; SCALE Obesity Prediabetes NN8022-1839 Study Group, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399\u20131409 (2017)","journal-title":"Lancet"},{"key":"1808_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","volume":"25","author":"A Lund","year":"2014","unstructured":"A. Lund, F.K. Knop, T. Vilsb\u00f8ll, Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Intern. Med. 25, 407\u2013414 (2014)","journal-title":"Eur. J. Intern. Med."},{"key":"1808_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde; LEAD-6 Study Group, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39\u201347 (2009)","journal-title":"Lancet"},{"key":"1808_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/dom.12076","volume":"15","author":"C Kapitza","year":"2013","unstructured":"C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, A. Hincelin-M\u00e9ry, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab. 15, 642\u2013649 (2013)","journal-title":"Diabetes Obes. Metab."},{"key":"1808_CR19","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0474","volume":"60","author":"MA Nauck","year":"2011","unstructured":"M.A. Nauck, G. Kemmeries, J.J. Holst, J.J. Meier, Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60, 1561\u20131565 (2011)","journal-title":"Diabetes"},{"key":"1808_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1177\/0091270008323750","volume":"48","author":"PA Kothare","year":"2008","unstructured":"P.A. Kothare, H. Linnebjerg, Y. Isaka, K. Uenaka, A. Yamamura, K.P. Yeo, A. de la Pe\u00f1a, C.H. Teng, K. Mace, M. Fineman, H. Shigeta, Y. Sakata, S. Irie, Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 48, 1389\u20131399 (2008)","journal-title":"J. Clin. Pharmacol."},{"key":"1808_CR21","first-page":"95","volume":"24","author":"S Kageyama","year":"2007","unstructured":"S. Kageyama, K. Hirao, A. Shimizu, Y. Matsumura, M. Zdravkovic, M.F. Rasmussen, S. Irie, Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue\u2015phase I studies in Japanese healthy subjects and subjects with type 2 diabetes. Endocrinol. Diabetol. 24, 95\u2013104 (2007). [in Japanese]","journal-title":"Endocrinol. Diabetol."},{"key":"1808_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2337\/db15-0893","volume":"65","author":"SS Thazhath","year":"2016","unstructured":"S.S. Thazhath, C.S. Marathe, T. Wu, J. Chang, J. Khoo, P. Kuo, H.L. Checklin, M.J. Bound, R.S. Rigda, B. Crouch, K.L. Jones, M. Horowitz, C.K. Rayner, The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes 65, 269\u2013275 (2016)","journal-title":"Diabetes"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1808-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:57:05Z","timestamp":1662393425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1808-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1808-9","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T.M., K.S., and W.O. have received lecture fees from Novo Nordisk; Y.H., K.S., and W.O. have received lecture fees from Eli Lilly; and Y.H. and W.O. have received lecture fees from Astra Zeneca. W.O. has received research support from Novo Nordisk, Eli Lilly, and Astra Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This exploratory, open-label, single-center study was approved by the ethics committee of Kobe University Graduate School of Medicine (approval no. 230021), conforms to the provisions of the Declaration of Helsinki, and is registered in the University Hospital Medical Information Network (UMIN000006858).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the individuals provided written informed consent to participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}